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Hypoxia-inducible factors (HIFs) are transcription factors that activate the transcription of genes necessary to circumvent to
hypoxic (low oxygen level) environments. In carcinogenesis, HIFs play a critical role. Indeed, HIF-1α has been validated as a
promising target for novel cancer therapeutics, even as clinical investigations have linked increased levels of HIF-1α with
aggressive cancer progression as well as poor patient prognosis. More so, inhibiting HIF-1 activity restricted cancer progression.
Therefore, HIF-1 is a viable target for cancer therapy. This may be expected considering the fact that cancer cells are
known to be hypoxic. In order to survive the hypoxic microenvironment, cancer cells activate several biochemical
pathways via the HIF-1α. Additionally, cellular and molecular insights have proved prospects of the HIF-1α pathway for
the development of novel anticancer treatment strategies. The biochemical importance of hypoxia-inducible factors (HIFs)
cannot be overemphasized as carcinogenesis, cancer progression, and HIFs are intricately linked. Therefore, this review
highlights the signiﬁcance of these linkages and also the prospects of HIFs as an alternative source of cancer therapies.
1. Introduction
The function and survival of living organisms are dependent
on the adequate supply of oxygen available to the cells.
Animals catabolize the sugar from plant using glycolysis,
citric acids, and oxidative phosphorylation in an aerobic
state. During these processes, oxygen is used as an electron
acceptor. Ineﬃcient transfer of electron results in a risk of
oxygen species generation. Electron escape can lead to
generation of superoxide anion and/or hydroxyl radicals,
all of which are examples of reactive oxygen species
(ROS) [1]. ROS have the potential to destroy the conﬁgura-
tion of biomolecules, which could result in cellular damage
or cell death [2]. Increased ROS production is associated with
deviations from physiological oxygen pressure (PO2) in the
electron transport chain. Therefore, tight regulation of cellu-
lar oxygen concentration through homeostatic mechanisms
is very essential. When the supply of oxygen fails to meet
the demand from tissues and cells, it is called hypoxia. All
solid tumors are characterized by hypoxia, as proliferation
of the tumor cells results in deprivation of oxygen due to
insuﬃcient blood ﬂow from abnormal tumor microvascula-
ture. Hypoxia induces stress in organisms either through
pathological or through nonpathological conditions [3].
The consequences of deregulation of hypoxia in cells
include breakage of DNA strand, oxidative DNA damage,
and gene aberration which hinder cell growth and eventual
cellular death. It also aﬀects the development of diseases such
as chronic lung disease, cancer, diabetes, ischemic heart
diseases, stroke, and advanced atherosclerosis [4]. Hypoxia
signaling adaptation in a cell is facilitated by the transcrip-
tional regulation family called hypoxia-inducible factor
(HIF). HIF is an oxygen-labile DNA-binding transcriptional
activator [5]. HIF controls multiple gene expression involved
in a process of cancer cell adaptation and progression [6].
Therefore, a better understanding of the molecular mecha-
nism of hypoxia in cancer cells could aﬀord the development
of more eﬀective therapy for solid tumors [7]. Additionally,
Hindawi
Oxidative Medicine and Cellular Longevity
Volume 2019, Article ID 8547846, 10 pages
https://doi.org/10.1155/2019/8547846
the available cancer therapies have not been desirably eﬀec-
tive [8], thus making research eﬀorts aimed at identifying
and developing newer cancer treatment strategies imperative.
In light of this, the current review is aimed at discussing
the prospects of hypoxia-inducible factors as alternative
treatment strategy for cancer.
2. Cellular Response to Hypoxia
Hypoxia can simply be deﬁned as a state of decreased oxy-
gen level in the cell or tissue when the oxygen provided
for use in the tissue is far less than what is actually
needed. A cell can be said to be hypoxia when the overall
oxygen pressure in the cell is less than 40mmHg [9]. Oxy-
gen is extremely important, especially in the cells and tis-
sues of mammals, mostly because of its importance in
respiration; it is extremely necessary in the ﬁnal step of
the electron transport chain, as the ﬁnal electron acceptor
in oxidative phosphorylation. Its presence increases the
chances of reactive oxygen species (ROS) generation,
which react with other biological molecules, resulting in
the alteration of the biochemical and physical properties
of the cell, causing either an upset of the delicate functions
or cell death [1]. Therefore, it can be seen that hypoxia is
a potentially lethal condition, for both the cell and the tis-
sue at large, if it is allowed to persist long enough. It
causes the oxygen-dependent process of respiration to
either slow down or cease completely, particularly the oxi-
dative phosphorylation process, which transfers the chem-
ical energy stored in C-H bonds into the high-energy
inorganic phosphate bonds found in ATP [10].
The stoppage of oxidative phosphorylation causes a
decrease in ATP, ultimately leading to the stoppage of the
ATP-dependent sodium potassium pump. This leads to an
imbalance of ions, creating an unbalanced cell environment;
the stoppage of the sodium potassium pump forces the cell
into employing anaerobic respiration as a means of sur-
vival, as its oxygen is cut oﬀ. This causes a buildup of lac-
tic acid in the cell, and the pH level drops, as the cell
becomes increasingly acidic. The acidity of the cell causes
it to swell, as it absorbs water from the environment in
an attempt to stabilize its pH. When the cell swells, the
permeability of the plasma membrane increases, allowing
the leaking of soluble enzymes and coenzymes. If hypoxia
persists, the continuing depletion of ATP leads to more
serious and pronounced structural anomalies. The com-
prehensive cellular structure is upset, resulting in loss of
the extracellular characteristics such as microvilli, and
irregular bulges are formed in the plasma membrane of
the cell and eventual cellular death.
Mammals have diﬀerent mechanisms for surviving the
events of hypoxia. The human response to a condition of
hypoxia involves physiological changes in respiratory, hema-
topoietic, and cardiovascular systems. The intake of oxygen is
maximized by increasing the functions of the cardiac sys-
tems, while the rate of oxygen distribution to individual cells
is improved by the acceleration of erythropoiesis. At the
cellular level, however, there are intricate factors that under-
lie these physiological changes in response to hypoxia. These
factors seek to restore the oxygenation, minimizing hypoxic
environment. These intricate factors are known as hypoxia-
inducible factors (HIFs) [11, 12].
3. Hypoxia-Inducible Factors (HIFs)
Hypoxia-inducible factor 1 is the heterodimer protein of two
subunits: HIF-1α and HIF-1β transcriptional factor [13, 14].
Each contains helix-loop- (HLS-) PER-ARNT-SIM (HLS-
PAS) domains that facilitate DNA binding and heterodimer-
ization. The beta subunit can also be referred to as the aryl
hydrocarbon receptor nuclear translocator (ARNT). The
alpha subunit is sensitive to oxygen, while the β subunit
(HIF-1β) is oxygen dependent [4]. HIF transcription factor
is the master regulator of the translational response, and it
is produced as a result of oxygen deﬁciency in the cell [1,
6]. HIF-α consists of diﬀerent alpha subunits: HIF-1α, HIF-
2α, and HIF-3α. The α subunit of HIF is tightly regulated
by HIF prolyl hydroxylases (PHDs). PHDs hydroxylate spe-
ciﬁc prolyl residues at the HIF-α subunits. von Hippel-
Lindau (VHL) tumor suppressors E3 ligase recognize
hydroxylated HIF-α subunit for degradation [4, 15]. In
addition, there is reduced transcriptional activities when
the factor inhibiting HIF (FIH) hydrolyses HIFs.
Decreased activities of PHD and FIH stabilize HIF-α dur-
ing hypoxia, leading to its translocation to the nucleus,
where it subsequently binds with HIF-β to form a com-
plex. This complex then binds target genes containing
the hypoxia responsive element and transactivates the gene
expression for diﬀerent signaling pathways [4]. Essentially,
HIF-1 can be referred to as a messenger which migrates
towards the nucleus to activate transcription responses to
hypoxia. HIF-1 has been involved in gene regulation
involving metastasis, growth, tumorigenesis, angiogenesis,
and invasion.
The vascular endothelial growth factor (VEGF) is an
example of the HIF-1 target gene in which its expression
is induced by hypoxia. Meanwhile, HIF-1 alone does not
determine the speciﬁc gene expression by individual cells,
as this is relatively determined by the functional interac-
tion of HIF-1 with other transcriptional factors that
control the activation of a selected subgroup of HIF-1 in
hypoxic cells [13].
4. General Functions of Hypoxia-Inducible
Factors (HIFs)
HIFs perform very essential roles, in a vast number of
mammalian conditions and reactions (Figure 1), and any
form of impairment of their functions can result in dire
consequences. Brieﬂy, few studies that highlight the roles of
the HIFs are described in the following.
4.1. Metabolism
(a) HIF-1α has been shown to cause a transition from
oxidative to glycolytic metabolism by inducing the
transcription of genes which support glycolytic
metabolism, PDK-1, coding for pyruvate
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dehydrogenase kinase-1, which inactivates pyruvate
dehydrogenase, inhibiting the reaction converting
pyruvate dehydrogenase, inhibiting the reaction
converting pyruvate to acetyl-CoA, preventing subse-
quent continuation into the Krebs cycle [16, 17],
LDHA, which encodes for lactate dehydrogenase,
that catalyzes the reaction converting pyruvate to lac-
tate [18], BNIP3 and BNIP3L, which mediate mito-
chondrial autophagy [19, 20]
(b) HIF-1 also mediates a change in the proteinous con-
ﬁguration of the enzyme cytochrome c oxidase, facil-
itating improvement in the transfer of electrons in
situations of hypoxia [21]
4.2. Embryonic Development. Most of the discoveries made
concerning the role of HIFs in embryonic development
were obtained from experiments conducted on mice by
quite a number of scientists. From these experiments, it
was discovered that
(a) the circulatory system depends on HIFs for normal
development. For example, mouse embryos defective
in the gene coding for the HIF (HIF-1α precisely)
died on their 11th day due to impaired erythropoiesis
and defective vascular system [22]
(b) mouse embryos which died on the 13th day due to
bradycardia or vascular defects are usually defective
in the genes coding for HIF-2α [23, 24]
(c) neonate mice may also die at birth due to pro-
longed lung maturation or at a few months after
birth, due to reactive oxygen species- (ROS-) medi-
ated organ failure, showing a role of HIFs in organ
development [25]
(d) increased HIF concentration in fetuses due to a
reduced blood ﬂow, which brings about a state of
prolonged hypoxia, could cause congenital
malfunctions
4.3. Diseases and Wound Healing. HIFs mediate protective
responses activated by the immune system response to dis-
ease or injury.
(a) In coronary heart disease, adenosine is extremely
important as it mediates preconditioning, an initial
immune response to hypoxia, where exposure of the
heart to short periods of hypoxia is followed by reper-
fusion, protecting the heart against subsequent, long
episodes of hypoxia. HIFs activate the transcription
of the genes that code for adenosine, which oﬀshoots
the aforementioned process [26]
(b) In the process of healing wounds, HIFs regulate the
release of regulatory protein of the immune system
from the wound which facilitates the mobilization
and direction of bone marrow-derived angiogenic
cells (BMDACs) to the site of the wound. BMDACs
then stimulate vasculogenesis or angiogenesis,
enabling the wound to heal [27]
(c) The eﬀect of HIFs in wound healing was found to be
impaired in mice with a high level of blood glucose. It
can be said that diabetes inhibits the action of HIFs
[28, 29]
(d) In peripheral heart disease (PAD) of which limb
ischaemia is a complication, HIFs mediate the
activation of various target genes which encode for
multiple angiogenic growth factors, including the
vascular endothelial growth factor (VEGF), stromal-
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Figure 1: The general function of hypoxia-inducible factors (HIFs).
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derived factor-1 (SDF-1), placental growth factor
(PGF-1), and stem cell factor. HIFs also oversee the
recruitment of BMDACs and recover tissue
perfusion
(e) HIFs also contribute to pathogenesis in some diseases
like hereditary erythrocytosis [22], cancer [30],
traumatic shock, pulmonary arterial hypertension,
and obstructive sleep apnea [27]
5. Regulation of HIFs
The expression of HIFs in the cellular environment is a
closely regulated process, where a lot of factors and reactions
are involved (Figure 2). Since HIFs have mainly to do with
oxygen levels in tissues, their system of regulation can be
considered under conditions of normal oxygen pressure
(normoxia) and conditions of abnormal oxygen pressure
(hypoxia).
In normoxic conditions, the HIF expression is constitu-
tive or rather inhibited, as they are not required. HIFs are
regulated in normoxic conditions by special oxygen sensitive
enzymes called prolyl hydroxylase domain enzyme (PHDs).
These enzymes regulate HIFs by hydroxylating the proline
residues found in the oxygen-dependent degradation
(ODD) domain of HIFs [31, 32]. The hydroxylation is carried
out by inserting an oxygen molecule into proline and another
into α-ketoglutarate, splitting it into succinate and carbon
dioxide. Since the PHDs use oxygen as a substrate, if oxygen
is not available, the process cannot take place [33]. The
hydroxylation process is a precursor to another very impor-
tant step, which is the ubiquitylation of the HIF by von
Hippel-Lindau (VHL) protein. The β subunit of the VHL
protein recognizes and binds the newly hydroxylated HIF.
The α subunit of the pVHL then assembles the pVHL ubiqui-
tin ligase, which marks the HIF for cleavage by the 26S pro-
teasome [34].
HIFs are also regulated by factors inhibiting HIFs
(FIHs) in normoxic conditions. They function by repres-
sing the transactivation of the HIF-α subunit. They do this
by hydroxylating asparagine residues in the C-terminal
transactivation domain of the HIFs using oxygen and α-
ketoglutarate as reactions, thus preventing the interaction
of the hypoxia-inducible factor with the p300 coactivator
protein [35, 36].
In hypoxic conditions, however, most of the above
processes are reversed. The PHDs, for instance, require
oxygen in order to hydroxylate the protein residues.
The hydroxylation of the HIF is thus stopped under
conditions of hypoxia, making it impossible for it to be
recognized and marked for degradation by the pVHL
ubiquitin ligase complex. As a result, HIFs are accumu-
lated in the nucleus.
The FIH-mediated hydroxylation is also reduced in the
conditions of hypoxia, allowing the HIFs react with the
transcriptional coactivators p300/CREB-binding protein
[37]. This transcriptional complex that is activated leads
to the transcription of a particular set of genes, as a part
of the cellular response to hypoxia, which includes, but
is not limited to, SLC2A1 (glycolysis) and VEGFA (angio-
genesis) [38].
HIFs may also be regulated in some other ways as follows:
(a) Muscle A-kinase anchoring protein (mAKAP):
AKAPs are scaﬀolding proteins that mediate the
assembly of multiprotein complexes. The mAKAPs
arrange the E3 ubiquitin ligase complex, aﬀecting
the stability and positioning of HIF in the active
site of the enzyme. A decrease in the availability
of the mAKAP would alter the stability of the
HIF complex
(b) Dimethyloxalylglycine (DMOG) is a well-known
opponent of α-ketoglutarate, which, if inhibited,
would abrogate the function of the hydroxylase,
thereby supporting HIF transcription [39]
(c) HIF is also stimulated by chelating agents of iron,
desferrioxamine and cobalt chloride (Adeyemi
et al., 2017). These chelators inhibit the hydroxylases
by displacing the iron ions present in their catalytic
centers
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(d) Doxorubicin (adriamycin) is a chemotherapeutic
drug used for cancer treatment. HIF-1 transcrip-
tional activity was inhibited by doxorubicin by pre-
venting the binding of HIF-1 to DNA [40, 41]
6. HIF Regulation and Mitochondria
Function in Cancer
The tricarboxylic acid (TCA) cycle catalyzes enzymatic reac-
tions that provide electrons in the form of the reducing
equivalents NADH and FADH2 to the electron transport
chain (ETC) in the mitochondrial matrix. Diﬀerent interme-
diates enter the cycle at a diﬀerent point from other pathways
but under hypoxia; glucose and fatty acid-derived carbons
are diverted from being broken down to acetyl-CoA, while
glutamine-derived carbons are diverted from being catabo-
lized to succinyl-CoA by the HIF-regulated genes.
Decreased oxidative phosphorylation could induce HIF
to upregulate lactate dehydrogenase (LDHA), thus regenerat-
ing NAD to maintain ATP production from glycolysis, and
thereby, divert pyruvate from breakdown into acetyl-CoA
which adversely suppress both TCA and ETC activities [17].
Cells adapt their metabolic programme under hypoxia
to maintain the reactions that rely on ATP produced by
oxidative phosphorylation. Generally, HIF-1 signaling sup-
ports the production of ATP anaerobic and downregula-
tion of oxidative phosphorylation, thereby reducing the
cell’s reliance on oxygen-dependent energy production
[17]. In relation to mitochondrial function, it has been
noted that the coexpression of HIF-1α and HIF-2α has
some opposing roles; however, they both in a similar
manner decrease a cell’s dependence on mitochondrial
oxidative phosphorylation [42].
Stress signaling pathways in the cell-like hypoxic
response [43], redox signaling [44], and unfolded protein
response [45] are activated in the mitochondria. As evident
in previous studies using mitochondrial DNA- (mtDNA-)
deﬁcient ρ0 cells in mouse xenograft models, it was observed
that the growth of the tumor is accelerated by the mitochon-
dria (Tan, et al., 2015; Yan et al., 2015). Cancer prognosis has
been linked clinically to single nucleotide variants in mtDNA
[46, 47]. However, mtDNA mutations or reduced mitochon-
drial content has caused decreased or low mitochondrial
function noticeable in many cancer types, including pancre-
atic, kidney, thyroid, and colon cancer [48–50]. This suggests
that there are some adaptive mechanisms during tumor
development in which mitochondrial activity is decreased.
7. MicroRNAs and Cancer
MicroRNAs also called miRNAs or miRs are small noncod-
ing RNAs which regulate gene expression at the posttran-
scriptional level. miRNAs repress mRNA translation and
degrades RNA targets [51]. miRNAs give a new insight into
cancer studies. miRNA genes are an important factor in the
pathogenesis of human cancer as they form central nodal
points in cancer development [52]. Understanding the mech-
anistic role of miRNAs in cancers still presents a challenge.
Reports have shown that molecular pathways of cancer are
regulated by miRNAs by targeting oncogenes and tumor sup-
pressor genes, involving the cancer-stem-cell development
pathway, angiogenesis, and drug resistance [53].
8. HIF-1 Responses in Tumor and Prospects for
Targeted Therapies
Tumors are noticeably characterized by a low oxygen level
of the tumor microenvironment. A partial pressure (PO2)
of less than 10mm is exhibited in solid tumors compared
to 45-65mm in normal tissues. There is inadequate blood
perfusion in acute or transient hypoxia, but chronic hyp-
oxia limits diﬀusion of oxygen in enlarged tumors. This
leads to the activation of both HIF-1 and HIF-2 with over-
expression of HIF-1α which is linked to metastasis and
mortality [4].
Cancer cells in humans have overexpression of HIF-1α,
but this is dependent on the type of cancer. The overex-
pressed HIF-1α has resulted into high mortality rate in
patient experiencing cancers of the breast, ovary, uterus,
cervix, brain, and oropharynx, while overexpression of
HIF-1α has been associated with decreased death rate with
head and neck cancer patients [54]. Although studies have
indicated that HIF-1α facilitates resistance to radiation and
chemotherapy, the inhibition of HIF-1α activation may be
useful in hindering cancer progression, thereby starving
the growing tumor cell of oxygen and the required nutrient
supply [54].
9. HIFs in Cancer Progression
The signiﬁcances of HIFs in diﬀerent stages in cancer cell for-
mation cannot be overemphasized (Figure 3). The diﬀerent
stages include angiogenesis, metastasis, metabolic repro-
gramme, invasion, epithelial-mesenchymal transition, and
cell proliferation and survival. With diﬀerent clinical and
experimental research establishing HIF as a cancer therapy
target, HIF-1α and HIF-2α levels are associated with metasta-
sis, vascularization, and tumor growth in both animal-based
and clinical-based studies. Several HIF-regulated genes that
are identiﬁed as important in cancer development are as
follows [1].
(a) Increase proliferation and survival of cell: a major
distinction between tumor cell and normal cell which
is initiated by autocrine signaling increased cell
proliferation and reduced cell death. The level of
ATP is an important determinant of cell apoptosis
as abundant glycolytic ATP leads to apoptosis during
hypoxic. Besides, deprivation of oxygen leads to the
inhibition of or decreased electron transport chain
processes, thus reducing the mitochondrial mem-
brane potential [55]. This results in the activation of
survival/growth factors which are expressed by
HIF-regulated genes such as insulin-like growth
factor-2 (IGF2), erythropoietin (EPO), vascular
endothelial growth factor (VEGF), Endothelin 1
(EDN1), transforming growth factor-α (TGFA),
and adrenomedullin [1]. These genes are the
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controlling hub of tumor pathways such as invasion,
proliferation, angiogenesis, and colonization of far-
oﬀ sites [5]
(b) Metabolic reprogramming: in order to meet cell
energy demands, glucose uptake is highly upregu-
lated in cancer cells compared to a normal cell. It
is the basis to detect metastases by imaging using
18-F-ﬂuorodeoxyglucose-positron emission tomog-
raphy (FDG-PET). HIF-1 also moderate the
tumor-related metabolic switch through the War-
burg eﬀect which is responsible for greater glucose
oxidation in anaerobic condition than in oxidative
phosphorylation. Critical eﬀects of this shift are
tumor microenvironment acidosis. The acidic envi-
ronment and the metabolic switch are responsible
for abundant metabolic intermediates that stimu-
lates tumor progression and aggressiveness [55].
HIF-1 facilitates the gene expression encoding glu-
cose transporter 1 and 3 and enzymes involved in
glucose conversion to lactose diﬀerent from those
found in normal cells such as hexokinase 1 and 2
(HK1, HK2), aldolase A and C (ALD-A, ALD-C),
phosphofructokinase L (PFKL), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), enolase A,
phosphoglycerate kinase 1 (PGK1), lactate dehy-
drogenase A (LDHA), and pyruvate kinase M2
(PKM2). HIF-1 increases the pyruvate dehydroge-
nase kinase-1 (PDK1) expression which inhibits
pyruvate dehydrogenase responsible for converting
pyruvate to acetyl-CoA before TCA cycle can
occur, thereby suppressing mitochondria function
and oxygen utilization [1]. Hexokinase and lactate
dehydrogenase A are oncogenic transcription fac-
tors for MYC targets. Under physiological condi-
tion, c-MYC activities are inhibited by HIF-1α,
but both c-MYC and HIF-1α work hand in hand
to induce the pyruvate dehydrogenase kinase-1
(PDK1) and hexokinase expression which result
in aerobic glycolysis and angiogenesis. Addition-
ally, HIF-1α inﬂuences cytochrome c oxidase sub-
unit 4 (COX4) switch under hypoxic condition to
give a homeostatic response which improves respi-
ration eﬃcacy at diﬀerent oxygen concentrations
[5]. Semenza [27] also revealed that HIF-1 may
also mediate the transketolase enzyme expression
in the hexose monophosphate pathway required
for nonoxidative production of ribose, a precursor
for nucleic acid [5, 27]
(c) Angiogenesis: new capillaries formed from already
existing vessels in response to low oxygen especially
in cancerous cell to deliver oxygen to the cells and
thereby encourage tumor growth [56]. The angio-
genic switch regulated by HIF-1 in hypoxic tumor
microenvironment may be connected with
increased oxygen consumption, while reducing oxy-
gen diﬀusion distance. Angiogenesis is an intricate,
well-ordered process which is essential for neo-
plasm formation. The mechanism comprises of
many genes, regulators, and pathways. Induction
of angiogenesis results in enlarged vascular density
and reduced oxygen diﬀusion distance [5]. Further-
more, HIF-1 also regulates the encoding genes for
angiogenic growth factor expressions. These include
angiopoietin 1 and 2, vascular endothelial growth
factor (VEGF), stromal-derived factor-1 (SDF-1),
platelet-derived growth factor B (PDGFB), and pla-
centa growth factor (PGF) [27]. A critical link
between hypoxia and angiogenesis is the discovery
of vascular endothelial growth factor (VEGF)
(d) Epithelial-mesenchymal transition: HIF-1 triggers
activation of repressor genes that inhibit proteins
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Figure 3: HIFs in cancer progression.
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responsible for cell to cell contact and rigid cytoskel-
eton. Examples of such repressor genes include tran-
scription factor 3 (TCF3), zinc ﬁnger E-box-binding
homeobox 1 and 2 (ZEB1, ZEB2), and inhibitor of
diﬀerentiation 2 (ID2). HIF-1 also facilitates a gene
expression that stimulates ﬂexible cytoskeleton like
TGFA and vimentin (VIM) [1]
(e) Invasion and metastasis: invasion and metastasis of
tumor cells are regulated by hypoxia. Metastasis is a
series of well-deﬁned events which is the basic reason
of cancer-related mortality. These events include the
local spread of tumor cells, intravasation, survival of
circulating tumor cells, and extravasation followed
by proliferation that leads to colonization. Activation
of genes regulated by HIF may improve metastasis in
multiple tumors. HIF-1 stimulates genetic transcrip-
tion such as proteases that degrade cathepsin C
(CTSC), matrix metalloproteinase 2, 9, and 14, and
the urokinase plasminogen activator receptor or
remodel lysyl oxidase (LOX); the extracellular matri-
ces within are of metastasis [5]
10. Inhibitors of HIF-1 in Cancer Therapy
Diﬀerent chemical compounds or drugs have been
revealed to block the activity of HIF through diﬀerent
molecular mechanisms (Table 1), including a reduced
synthesis of HIF-1α protein (mTOR inhibitors, cardiac
glycosides, topoisomerase inhibitor, and synthetic oligonu-
cleotides), decreased HIF-1α mRNA levels (aminoﬂavone
component of prodrug AFP-464), increased HIF-1α break-
down (HSP90 inhibitors, antioxidants, and Se-methylsele-
nocysteine), reduced heterodimerization of HIF subunit
(acriﬂavine), decreased DNA binding to the HIF (anthra-
cyclines and echinomycin), and reduced transcriptional
activity [1].
(a) Inhibitors of the HIF-1 mRNA expression: HIF-1
increase is regulated predominantly at the degrada-
tion or translation of protein, and these pathways
are the targets of most HIF-1 inhibitors. However,
under hypoxic conditions, HIF-1 mRNA levels can
act as a limiting factor thereby aﬀecting protein
translation [57]. Aminoﬂavone (AF) is an agent that
aﬀects the HIF-1 mRNA expression. It acts as a
ligand of aryl-hydrocarbon receptor (AhR) and pres-
ently being used in clinical trials in metastatic cancer
patients [57]
(b) Inhibitors of HIF-1 protein translation: numerous
agents may aﬀect the HIF-1 protein synthesis rate,
including tyrosine kinase inhibitor, topoisomerase I
and II inhibitor, cyclin-dependent kinase inhibitor,
oncogenic pathway inhibitor, and thioredoxin
reductase inhibitor. One of the earlier agents used
for HIF-1 protein translation is topotecan, a sec-
ond line chemotherapy for lung cancer or ovarian
cancer. Topotecan is a camptothecin analogue
which in the presence of DNA replication generate
double strand DNA breaks and cytotoxicity,
thereby poisons topoisomerase I by inducing the
formation of stable Top1-DNA cleavage complexes
[57]. Another class of agents that aﬀect HIF-1 pro-
tein translation is cardiac glycosides. Digoxin in
particular has been identiﬁed as a HIF-1 potent
inhibitor. Digoxin inhibits HIF-1 translation using
mTOR-independent mechanism and also exhibits
antitumor activity [55]. PX-478 is another HIF-1
inhibitor presently in phase I clinical trials in
advanced metastatic cancer patients. It showed
antitumor activity in tumor xenograft models,
which correlate with the HIF-1 expression [57]
EZN-2968 is a RNA modulator composed of synthetic
antisense oligonucleotide that binds and inhibits speciﬁcally
the HIF-1α mRNA expression [6, 58]. There is a dose-
dependent downregulation of HIF-1α mRNA after it binds
to EZN-2968 leading to inhibition in both normoxia and
hypoxia [58]. In mice implanted with DU-145 human pros-
tate cancer cells, EZN-2968 treatment showed tumor reduc-
tion. Clinically, evaluation of EZN-2968 treatment of 4 out
of 6 patients with paired tumor biopsies showed reduced
HIF-1α mRNA in posttreatment biopsies while two patients
had a reduced level of mRNA and HIF-1α protein of target
genes in biopsies [59]. This revealed a pilot proof of HIF-1α
mRNA and protein expression modulation in response to
EZN-2968 thereby indicating inhibition of HIF-1α mRNA
has potential as a target for cancer therapy [60].
11. Conclusion
The mechanism for cellular oxygen homeostasis and its
response to a low oxygen state is basically facilitated by the
Table 1: Some HIF inhibitors and targets.
Agents Inhibitory mechanisms Targeting HIF-1 Targeting HIF-2 Reference no.
EZN-2968 HIF-1 mRNA expression √ — Jeong, et al., [60]
EZN-2208 HIF-1 mRNA expression √ — Coltella, et al., [61]
Topotecan HIF-1 mRNA translation √ — Rapisarda, et al., [62]
HIF-1α inhibitor HIF-α transcriptional activity √ √ Cui, et al., [63]
PX-12 HIF-α transcriptional activity √ — Raninga, et al., [64]
Acriﬂavine HIF transcriptional activity √ √ Lee, et al., [40, 41]
Echinomycin HIF DNA binding √ — Yu, et al., [65]
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HIF pathway. Additionally, the regulation or dysregulation
of the HIF pathway is a major determinant in cancer metas-
tasis, and this correlates with a poor cancer prognosis.
Because of the roles that it plays in cancer progression, HIF
has become an attractive target for chemotherapy against
cancerous cells. Perhaps, the combined usage of conventional
treatment and HIF inhibitors may prove to be useful
clinically.
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